RJR-2403Nicotinic receptor agonist,highly selective CAS# 15585-43-0 |
- RJR-2403 oxalate
Catalog No.:BCC1902
CAS No.:220662-95-3
- Varenicline
Catalog No.:BCC4155
CAS No.:249296-44-4
- EVP-6124 hydrochloride
Catalog No.:BCC1567
CAS No.:550999-74-1
- EVP-6124
Catalog No.:BCC1566
CAS No.:550999-75-2
- LX-1031
Catalog No.:BCC1712
CAS No.:945976-76-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 15585-43-0 | SDF | Download SDF |
PubChem ID | 5310967 | Appearance | Powder |
Formula | C10H14N2 | M.Wt | 162.23 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Rivanicline; Metanicotine | ||
Solubility | Soluble in DMSO | ||
Chemical Name | (E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine | ||
SMILES | CNCCC=CC1=CN=CC=C1 | ||
Standard InChIKey | JUOSGGQXEBBCJB-GORDUTHDSA-N | ||
Standard InChI | InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | RJR-2403 is an agonist of neuronal nicotinic receptor with Ki value of 26 nM for α4β2 receptor. | |||||
Targets | α4β2 nicotinic receptor | |||||
IC50 | 26 nM (Ki) |
RJR-2403 Dilution Calculator
RJR-2403 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.1641 mL | 30.8204 mL | 61.6409 mL | 123.2818 mL | 154.1022 mL |
5 mM | 1.2328 mL | 6.1641 mL | 12.3282 mL | 24.6564 mL | 30.8204 mL |
10 mM | 0.6164 mL | 3.082 mL | 6.1641 mL | 12.3282 mL | 15.4102 mL |
50 mM | 0.1233 mL | 0.6164 mL | 1.2328 mL | 2.4656 mL | 3.082 mL |
100 mM | 0.0616 mL | 0.3082 mL | 0.6164 mL | 1.2328 mL | 1.541 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
RJR-2403 Description:
Ki: RJR-2403 compound binds with high affinity to [3H]nicotine binding sites in rat brain (Ki 526 nM) but possesses weak affinity (36 mM) for the 125I-labeled a-bungarotoxin-sensitive nAChR subtype [1].
RJR-2403 (TC-2403, Rivanicline, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease, but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis. RJR-2403 also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release, and so it could potentially also have other applications.
In vitro: Prevous in vitro results suggest that RJR-2403 interacts with higher potency at CNS nAChR sub-types than at muscle, ganglionic or enteric nAChRs and has higher selectivity for CNS vs. muscle or ganglionic nAChRs than does nicotine. [2].
In vivo: The data from an in vivo study demonstrate the efficacy of oral RJR 2403 in improving cognitive performance and the long duration of action of RJR 2403 in young adult rats. In contrast, no significant memory improvement was seen in aged rats aged (24–26 months old) after RJR 2403 administration. The inability of RJR 2403 to enhanced cognitive functions in aged rats might be related to the decrease in the number of α4β2 nicotinic receptors, which occurs with age. A similar decreased responsiveness in aged rats has been seen with nicotine. The persistence of action of RJR 2403 provides additional promise for its potential as a treatment for cognitive dysfunction [3].
Clinical trial: Up to now, RJR-2403 is still in the preclinical development stage.
Reference:
[1] Damaj MI, Glassco W, Aceto MD, Martin BR.Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther. 1999;291(1):390-8.
[2] Bencherif M, Lovette ME, Fowler KW, Arrington S, Reeves L, Caldwell WS, Lippiello PM. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther. 1996;279(3):1413-21.
[3] Edward D. Levin and N. Channelle Christopher. Persistence of nicotinic agonist RJR 2403-induced working memory improvement in rats. Drug Development Research. 55(2):97–103, 2002
- BW 373U86
Catalog No.:BCC5798
CAS No.:155836-50-3
- 5-O-Methylhierochin D
Catalog No.:BCN4526
CAS No.:155836-29-6
- 25-O-Methylalisol A
Catalog No.:BCN3456
CAS No.:155801-00-6
- 3-beta-O-(cis-p-Coumaroyl)corosolic acid
Catalog No.:BCN1553
CAS No.:155800-17-2
- 4-IBP
Catalog No.:BCC6777
CAS No.:155798-08-6
- Hierochin D
Catalog No.:BCN1702
CAS No.:155759-02-7
- Peujaponiside
Catalog No.:BCN8261
CAS No.:155740-16-2
- Pizotifen
Catalog No.:BCC4215
CAS No.:15574-96-6
- Mecarbinate
Catalog No.:BCC4919
CAS No.:15574-49-9
- Isomagnolone
Catalog No.:BCN1701
CAS No.:155709-41-4
- Simonsinol
Catalog No.:BCN1700
CAS No.:155709-40-3
- Notoginsenoside Ft1
Catalog No.:BCN6434
CAS No.:155683-00-4
- 9,10-Dimethoxycanthin-6-one
Catalog No.:BCN3106
CAS No.:155861-51-1
- LE 135
Catalog No.:BCC7242
CAS No.:155877-83-1
- Gipsoside
Catalog No.:BCN8482
CAS No.:15588-68-8
- Edultin
Catalog No.:BCC8321
CAS No.:15591-75-0
- Rabdoternin F
Catalog No.:BCN6399
CAS No.:155977-87-0
- 4-Hydroxyphenylacetic acid
Catalog No.:BCN4795
CAS No.:156-38-7
- Sodium butyrate
Catalog No.:BCC4720
CAS No.:156-54-7
- H-HoArg-OH
Catalog No.:BCC3226
CAS No.:156-86-5
- Angelidiol
Catalog No.:BCN7964
CAS No.:156009-77-7
- Qianhucoumarin E
Catalog No.:BCN3506
CAS No.:156041-02-0
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- SGC 0946
Catalog No.:BCC2216
CAS No.:1561178-17-3
Antiamnestic effect of alpha7-nicotinic receptor agonist RJR-2403 in middle-aged ovariectomized rats with Alzheimer type dementia.[Pubmed:17603674]
Bull Exp Biol Med. 2006 Dec;142(6):700-2.
The effects of chronic combined treatment with alpha7-nicotinic cholinergic receptor agonist RJR-2403 (1.0 mg/kg intraperitoneally) or alpha7-nicotinic cholinergic receptor antagonist mecamylamine (1.0 mg/kg intraperitoneally) and 17beta-estradiol (0.5 microg per rat intramuscularly) for 10 days on passive avoidance retention were studied in middle-aged (15 months) ovariectomized rats with experimental Alzheimer type dementia. Chronic treatment with RJR-2403 and 17beta-estradiol had a pronounced antiamnestic effect under conditions of Alzheimer type dementia in middle-aged ovariectomized rats.
[Co-administration of RJR-2403 with low dose of 17beta-estradiol on spatial learning in ovariectomized rats].[Pubmed:24340617]
Patol Fiziol Eksp Ter. 2013 Jul-Sep;(3):37-41.
The aim of this work was to study the influence of stimulation or blockade Nalpha7-cholinoreceptors on dynamics of spatial learning in water Morris maze and on behavior in the "open field" test in adult ovariectomized (OVX) females given with a low dose of 17beta-estradiol. Agonist of Nalpha7-cholinoreceptors - RJR-2403 (1.0 mg/kg, i.p.) or antagonist of Nalpha7-cholinoreceptors - mecamylamine (1.0 mg/kg, i.p.) treated chronically (14 days) alone and in a combination with low dose of 17beta-estradiol (0.5 micro/rat, s.c.) to OVX rats. Co-administration of RJR-2403 with low dose of 17beta-estradiol completely restored impaired spatial learning in water Morris maze in OVX females. Moreover, OVX rats treated with RJR-2403 and low dose of 17beta-estradiol demonstrated increased exploratory and grooming behavior in the "open field" test. Both mecamylamine alone and in combination with low dose of 17beta-estradiol failed to influence on spatial learning and failed to modify behavior in the "open field" test in OVX rats. The results of the present study suggest a positive effect of RJR-2403 in combination with low dose of 17beta-estradiol on spatial learning at estrogen deficiency.
[Chronic administration of RJR-2403 in combination with low-dose of 17beta-estradiol corrects passive avoidance learning in ovariectomized rats].[Pubmed:23901460]
Eksp Klin Farmakol. 2013;76(5):3-6.
The aim of this work was to study the effect of stimulation or blockade of Na7-cholinoreceptors with a low dose of 17beta-estradiol on the passive avoidance performance and behavior in the open-field test in adult ovariectomized (OVX) female rats. Agonist of Na7-cholinoreceptors RJR-2403 (1.0 mg/kg, i.p.) or antagonist of Na7-cholinoreceptors mecamylamine (1.0 mg/kg, i.p.) treated chronically (14 days) alone and in a combination with low dose of 17beta-estradiol (0.5 microg/rat, s.c.) to OVX rats. Co-administration of RJR-2403 with low dose of 17P-estradiol completely restored impaired passive avoidance performance in OVX females. OVX rats treated with RJR-2403 and low dose of 17beta-estradiol demonstrated increased exploratory and grooming behavior in the open-field test. Both mecamylamine alone and in combination with low dose of 17beta-estradiol failed to influence the passive avoidance learning and failed to modify behavior in the open-field test in OVX rats. The results of the present study suggest positive effect of RJR-2403 in combination with low dose of 17beta-estradiol on passive avoidance learning at estrogen deficiency.
The nicotinic agonist RJR-2403 compensates the impairment of eyeblink conditioning produced by the noncompetitive NMDA-receptor antagonist MK-801.[Pubmed:16644113]
Neurosci Lett. 2006 Jul 10;402(1-2):102-7.
The classical conditioning of eyelid responses using trace paradigms is a hippocampal-related model of associative learning, involving the activation of N-methyl-D-aspartate (NMDA) receptors. We have evaluated here the effects of NMDA-receptor blockage with the selective noncompetitive antagonist (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (dizocilpine, MK-801). Mice were implanted with stimulating electrodes on the supraorbitary nerve and with recording electrodes in the ipsilateral orbicularis oculi muscle. Animals were conditioned with a trace shock-SHOCK paradigm. MK-801-injected animals (0.02 mg/kg) seemed unable to acquire this type of associative learning task, but the latency and amplitude of their unconditioned eyelid responses was not affected by drug administration. The administration of the nicotinic agonist (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403; 2 mg/kg) was able to restore completely the acquisition of the conditioned response when administered both before and after MK-801. In vitro recordings of field excitatory postsynaptic potentials (fEPSPs) evoked in the hippocampal CA1 area by the electrical stimulation of the Schaffer collateral pathway indicates that RJR-2403 application to the bath enhance the release of glutamate by a presynaptic mechanism. These findings reveal that nicotinic acetylcholine receptors enhance glutamatergic transmission in hippocampal circuits involved in the acquisition of associative learning.